Scimedico, LLC is a New Jersey healthcare company that maintains pathology labs and encourages collaboration with clients. A blog post from Scimedico discusses research from Northwestern University on developments in brain tumor classification that impact pathologists' work. For over 100 years, pathologists classified brain tumors by examining samples under a microscope, but affordable genetic sequencing and projects like TCGA have transformed their practice to focus more on genetic biomarkers for accurate classification and grading.

1. Biomarkers -
Transforming
Pathologists’ Brain
Tumor Evaluations

2. Scimedico, LLC, is an established New Jersey provider of health
care solutions that emphasizes maintenance of necropsy and
pathology laboratories. Scimedico, LLC, encourages a
collaborative relationship with clients that includes clinical labs,
hospitals, and medical systems. A blog article from Scimedico,
LLC, highlights Northwestern University’s research on brain tumor
classification developments and how this impacts the work of
pathologists.
Over the past 100 years, pathologists have been responsible for
grading and classifying brain tumors. Through evaluating samples
under a microscope, they determine biological aggressiveness and
tumor class, as well as corollary findings involving new blood
vessels, cell death, cell morphology, and cell proliferation.
In recent years, this traditional evaluative practice has been
transformed by the introduction of relatively affordable genetic
sequencing and efforts such as The Cancer Genome Atlas (TCGA).

3. This has shifted the pathologists’ focus toward less visible but
more accurate genetic biomarkers as a basis of classification and
grading.